SCHEMBL3754733

SCHEMBL3754733

[SiH3][C@H]1O[C@H]1c1cccc2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.50
KDM1A O60341 1/20 0.47
SLC6A4 P31645 5/20 0.45
SLC6A2 P23975 2/20 0.45
SLC6A3 Q01959 2/20 0.45
ALDH1A1 P00352 4/20 0.42
HPGD P15428 2/20 0.42
KDM4E B2RXH2 1/20 0.42
TDP2 O95551 1/20 0.42
MAPT P10636 1/20 0.42
ALOX12 P18054 1/20 0.42
MAPK1 P28482 1/20 0.42
CASP3 P42574 1/20 0.42
HTT P42858 1/20 0.42
GALK1 P51570 1/20 0.42
BLM P54132 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7915108 0.78 EPHX1 (0.50) EPHX1KDM1ASLC6A4SLC6A2SLC6A3
SCHEMBL10078485 0.74 EPHX1 (0.46) EPHX1KDM1ASLC6A4SLC6A2SLC6A3
SCHEMBL8766883 0.74 EPHX1 (0.50) EPHX1KDM1ASLC6A4SLC6A2SLC6A3
SCHEMBL9026176 0.72 EPHX1 (0.45) EPHX1KDM1ASLC6A4SLC6A2SLC6A3
SCHEMBL11116467 0.71 SLC6A4 (0.45) EPHX1KDM1ASLC6A4SLC6A2SLC6A3
SCHEMBL9026204 0.70 EPHX1 (0.67) EPHX1KDM1ASLC6A4SLC6A2SLC6A3
SCHEMBL10300820 0.70 SLC6A4 (0.53) EPHX1KDM1ASLC6A4SLC6A2SLC6A3
SCHEMBL2464189 0.70 SLC6A4 (0.53) EPHX1KDM1ASLC6A4SLC6A2SLC6A3
SCHEMBL5852684 0.70 SLC6A4 (0.53) EPHX1KDM1ASLC6A4SLC6A2SLC6A3
SCHEMBL9390206 0.70 KDM1A (0.47) EPHX1KDM1ASLC6A4SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305338-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE CIS-SILYL OLEFIN OXIDE COMPOUND NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305338-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE CIS-SILYL OLEFIN OXIDE COMPOUND CYP51A1, MSMO1, SQLE EPHX1 1780/4885KDM1A 2373/4885SLC6A4 3755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.